Search research articles
Contact Us
Filters
Showing results (1-10 of 16) with videos related to
Page
of 2
Sort By:
Clinical and Experimental Gastroenterology
|
April 15, 2024
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation
Prashant Singh, Gregory S Sayuk, David P Rosenbaum, et al.
Acta Physiologica (Oxford, England)
|
August 11, 2023
Increased Slc34a2 expression and paracellular phosphate permeability contribute to high intestinal phosphate absorption in young mice
Tate MacDonald, Megan R Beggs, Debbie O'Neill, et al.
Clinical and Experimental Gastroenterology
|
June 11, 2024
Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)
Brian E Lacy, David Rosenbaum, Susan Edelstein, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation
|
July 11, 2024
Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure
Kathleen M Hill Gallant, Stuart M Sprague, David P Rosenbaum, et al.
Molecular and Cellular Biology
|
December 24, 2008
The double-histone-acetyltransferase complex ATAC is essential for mammalian development
Sebastián Guelman, Kenji Kozuka, Yifan Mao, et al.
Digestive Diseases and Sciences
|
September 28, 2011
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials
Matthew Siegel, Mitchell E Garber, Andrew G Spencer, et al.
Clinical Pharmacology in Drug Development
|
September 23, 2016
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders
Susanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 22, 2024
NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons
Andrew J King, Lin Chang, Qian Li, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na<sup>+</sup>/H<sup>+</sup> Exchanger Isoform 3
Jeffrey W Jacobs, Michael R Leadbetter, Noah Bell, et al.
Stem Cell Reports
|
November 21, 2017
Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform
Kenji Kozuka, Ying He, Samantha Koo-McCoy, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 16) with videos related to
Sort By:
Page
of 2
Clinical and Experimental Gastroenterology
|
April 15, 2024
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation
Prashant Singh, Gregory S Sayuk, David P Rosenbaum, et al.
Acta Physiologica (Oxford, England)
|
August 11, 2023
Increased Slc34a2 expression and paracellular phosphate permeability contribute to high intestinal phosphate absorption in young mice
Tate MacDonald, Megan R Beggs, Debbie O'Neill, et al.
Clinical and Experimental Gastroenterology
|
June 11, 2024
Intestinal Permeability, Irritable Bowel Syndrome with Constipation, and the Role of Sodium-Hydrogen Exchanger Isoform 3 (NHE3)
Brian E Lacy, David Rosenbaum, Susan Edelstein, et al.
Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation
|
July 11, 2024
Tenapanor: A Phosphate Absorption Inhibitor for the Management of Hyperphosphatemia in Patients With Kidney Failure
Kathleen M Hill Gallant, Stuart M Sprague, David P Rosenbaum, et al.
Molecular and Cellular Biology
|
December 24, 2008
The double-histone-acetyltransferase complex ATAC is essential for mammalian development
Sebastián Guelman, Kenji Kozuka, Yifan Mao, et al.
Digestive Diseases and Sciences
|
September 28, 2011
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials
Matthew Siegel, Mitchell E Garber, Andrew G Spencer, et al.
Clinical Pharmacology in Drug Development
|
September 23, 2016
Preclinical and Healthy Volunteer Studies of Potential Drug-Drug Interactions Between Tenapanor and Phosphate Binders
Susanne Johansson, Maria Leonsson-Zachrisson, Mikael Knutsson, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology
|
January 22, 2024
NHE3 inhibitor tenapanor maintains intestinal barrier function, decreases visceral hypersensitivity, and attenuates TRPV1 signaling in colonic sensory neurons
Andrew J King, Lin Chang, Qian Li, et al.
ACS Medicinal Chemistry Letters
|
July 21, 2022
Discovery of Tenapanor: A First-in-Class Minimally Systemic Inhibitor of Intestinal Na<sup>+</sup>/H<sup>+</sup> Exchanger Isoform 3
Jeffrey W Jacobs, Michael R Leadbetter, Noah Bell, et al.
Stem Cell Reports
|
November 21, 2017
Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform
Kenji Kozuka, Ying He, Samantha Koo-McCoy, et al.
Page
of 2